chemoimmunotherapy, durvalumab, interstitial lung disease, pneumonitis, small-cell lung cancer
Non-small cell lung cancer, Performance status 2, Immune checkpoint inhibitors, Real-world evidence, First-line therapy
NSCLC, immunotherapy, EGFR-TKI, RMST, survival pattern